Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - hiv infections - antivirals for systemic use - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight.prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg).in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista.prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection.prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated.for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista.prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection.prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg).prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve.art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

İsrail - İngilizce - Ministry of Health

j-c health care ltd - darunavir as ethanolate - film coated tablets - darunavir as ethanolate 75 mg - darunavir - darunavir - adult patients:prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv -1) infection. this indication is based on analyses of plasma hiv-1 rna levels and cd4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment - naive and treatment-experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients .pediatric patients:prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of hiv-1 infection in treatment-experienced pediatric patients 6 years of age and older .this indication is based on 24 week analyses of plasma hiv-1 rna levels and cd4+ cell counts from an open-label phase 2 trial in antiretroviral treatment-experienced pediatric patients 6 to < 18 years of age. in treatment-experienced adult and pediatric patients, the following points should be considered when initiating therapy with prezista/rtv: - treatment history and, when available, genotypic or phenotypic testing, should guide the use of prezista/rtv. - the use of other active agents with prezista/rtv is associated with a greater likelihood of treatment response.

İsrail - İngilizce - Ministry of Health

j-c health care ltd - darunavir as ethanolate - film coated tablets - darunavir as ethanolate 150 mg - darunavir - darunavir - adult patients:prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv -1) infection. this indication is based on analyses of plasma hiv-1 rna levels and cd4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment - naive and treatment-experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients .pediatric patients:prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of hiv-1 infection in treatment-experienced pediatric patients 6 years of age and older .this indication is based on 24 week analyses of plasma hiv-1 rna levels and cd4+ cell counts from an open-label phase 2 trial in antiretroviral treatment-experienced pediatric patients 6 to < 18 years of age. in treatment-experienced adult and pediatric patients, the following points should be considered when initiating therapy with prezista/rtv: - treatment history and, when available, genotypic or phenotypic testing, should guide the use of prezista/rtv. - the use of other active agents with prezista/rtv is associated with a greater likelihood of treatment response.

ABD - İngilizce - NLM (National Library of Medicine)

state of florida doh central pharmacy - darunavir ethanolate (unii: 33o78xf0bw) (darunavir - unii:yo603y8113) - darunavir ethanolate 400 mg - prezista® , co-administered with ritonavir (prezista/ritonavir), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection. this indication is based on analyses of plasma hiv rna levels and cd4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment-naïve and treatment-experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients. prezista, co-administered with ritonavir (prezista/ritonavir), and with other antiretroviral agents, is indicated for the treatment of hiv infection in pediatric patients 6 years of age and older [see use in specific populations (8.4) ]. this indication is based on 24-week analyses of plasma hiv rna levels and cd4+ cell counts from an open-label phase 2 trial in antiretroviral treatment-experienced pediatric patients 6 to < 18 years of age. in treatment-experienced adult and pediatric patients, the following poi

ABD - İngilizce - NLM (National Library of Medicine)

remedyrepack inc. - darunavir ethanolate (unii: 33o78xf0bw) (darunavir - unii:yo603y8113) - darunavir 600 mg - prezista ® , co-administered with ritonavir (prezista/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection in adult and pediatric patients 3 years of age and older [see use in specific populations (8.4) and clinical studies (14)] . co-administration of prezista/ritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). these drugs and other contraindicated drugs (which may lead to reduced efficacy of darunavir) are listed in table 6 . due to the need for co-administration of prezista with ritonavir, please refer to ritonavir prescribing information for a description of ritonavir contraindications. co-administration of prezista/ritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are

ABD - İngilizce - NLM (National Library of Medicine)

janssen products lp - darunavir ethanolate (unii: 33o78xf0bw) (darunavir - unii:yo603y8113) - darunavir 75 mg - prezista, co-administered with ritonavir (prezista/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection in adult and pediatric patients 3 years of age and older [see use in specific populations (8.4)and clinical studies (14)] . co-administration of prezista/ritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). examples of these drugs and other contraindicated drugs (which may lead to reduced efficacy of darunavir) are listed below [see drug interactions (7.3)] . due to the need for co-administration of prezista with ritonavir, please refer to ritonavir prescribing information for a description of ritonavir contraindications. - alpha 1-adrenoreceptor antagonist: alfuzosin - anti-gout: colchicine, in patients with renal a

ABD - İngilizce - NLM (National Library of Medicine)

physicians total care, inc. - darunavir ethanolate (unii: 33o78xf0bw) (darunavir - unii:yo603y8113) - darunavir 400 mg - prezista® , co-administered with ritonavir (prezista/ritonavir), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection. this indication is based on analyses of plasma hiv-1 rna levels and cd4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment-naïve and treatment-experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients. prezista, co-administered with ritonavir (prezista/ritonavir), and with other antiretroviral agents, is indicated for the treatment of hiv-1 infection in pediatric patients 3 years of age and older [see use in specific populations (8.4) ]. this indication is based on 24-week analyses of plasma hiv-1 rna levels and cd4+ cell counts from 2 open-label phase 2 trials in antiretroviral treatment-experienced pediatric patients (one trial in patients 6 to less than 18 years of age and one trial in patients 3 to less t

ABD - İngilizce - NLM (National Library of Medicine)

remedyrepack inc. - darunavir ethanolate (unii: 33o78xf0bw) (darunavir - unii:yo603y8113) - prezista, co-administered with ritonavir (prezista/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection in adult and pediatric patients 3 years of age and older [see use in specific populations (8.4) and clinical studies (14)] . co-administration of prezista/ritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). these drugs and other contraindicated drugs (which may lead to reduced efficacy of darunavir) are listed below [see drug interactions (7.3)] . due to the need for co-administration of prezista with ritonavir, please refer to ritonavir prescribing information for a description of ritonavir contraindications. - alpha 1-adrenorecept

ABD - İngilizce - NLM (National Library of Medicine)

crystal curam - camphor 4.8% menthol 1.2%, eucalyptus oil 2.6%, cough suppressant & topical analgesic, cough suppressant, cough suppressant & topical analgesic - - when applied to chest and throat, temporarily relieves cough due to minor throat and bronchial irritation associated with the common cold - when applied to muscles and joints, temporarily relieves minor aches and pains of muscles and joints

ABD - İngilizce - NLM (National Library of Medicine)

crystal curam - petrolatum (unii: 4t6h12bn9u) (petrolatum - unii:4t6h12bn9u) - skin protectant - temporarily protects minor cuts, scrapes, burns and sunburn - temporarily protects and helps relieve chapped or cracked skin - helps protect from the drying effects of wind and cold weather - helps treat and prevent diaper rash - helps seal out wetness - condition worsens - symptoms last for more than 7 days or clean up and occur again in a few days - deep or puncture wounds - animal bites - serious burns